LivaNova (NASDAQ:LIVN) Given New $75.00 Price Target at Needham & Company LLC

LivaNova (NASDAQ:LIVN) had its price target increased by Needham & Company LLC from $72.00 to $75.00 in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts also recently issued reports about the stock. Robert W. Baird boosted their price target on shares of LivaNova from $58.00 to $66.00 and gave the stock a neutral rating in a research note on Thursday, May 2nd. StockNews.com raised shares of LivaNova from a hold rating to a buy rating in a research note on Thursday, April 25th. Stifel Nicolaus boosted their price target on shares of LivaNova from $70.00 to $72.00 and gave the stock a buy rating in a research note on Thursday, July 25th. Finally, Mizuho boosted their price target on shares of LivaNova from $75.00 to $80.00 and gave the stock a buy rating in a research note on Thursday, May 2nd. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $65.83.

LivaNova Trading Down 2.8 %

Shares of NASDAQ LIVN opened at $46.98 on Wednesday. LivaNova has a 1-year low of $42.75 and a 1-year high of $64.47. The company has a market cap of $2.54 billion, a PE ratio of -78.30 and a beta of 0.99. The company has a current ratio of 3.45, a quick ratio of 2.71 and a debt-to-equity ratio of 0.49. The company has a 50-day moving average of $54.01 and a two-hundred day moving average of $54.39.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, May 1st. The company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.28. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. The company had revenue of $294.90 million during the quarter, compared to the consensus estimate of $278.17 million. During the same period in the previous year, the firm posted $0.43 earnings per share. The company’s revenue was up 12.0% on a year-over-year basis. As a group, equities analysts expect that LivaNova will post 2.6 earnings per share for the current fiscal year.

Insider Buying and Selling at LivaNova

In other LivaNova news, Director Daniel Jeffrey Moore sold 56,623 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $60.11, for a total value of $3,403,608.53. Following the completion of the sale, the director now owns 27,534 shares of the company’s stock, valued at $1,655,068.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Louisiana State Employees Retirement System acquired a new position in shares of LivaNova in the fourth quarter valued at approximately $781,000. Campbell & CO Investment Adviser LLC acquired a new position in shares of LivaNova in the fourth quarter valued at approximately $2,090,000. Trexquant Investment LP acquired a new position in shares of LivaNova in the fourth quarter valued at approximately $1,079,000. Norges Bank acquired a new position in shares of LivaNova in the fourth quarter valued at approximately $26,064,000. Finally, BNP Paribas Financial Markets boosted its holdings in LivaNova by 88.6% during the first quarter. BNP Paribas Financial Markets now owns 42,121 shares of the company’s stock worth $2,356,000 after purchasing an additional 19,783 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.